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Abstract Hippocampal pathology was shown to be
extensive in multiple sclerosis (MS) and is associated with
memory impairment. In this post-mortem study, we
investigated hippocampal tissue from MS and Alzheimer’s
disease (AD) patients and compared these to non-neuro-
logical controls. By means of biochemical assessment,
(immuno)histochemistry and western blot analyses, we
detected substantial alterations in the cholinergic neuro-
transmitter system in the MS hippocampus, which were
different from those in AD hippocampus. In MS hippo-
campus, activity and protein expression of choline
acetyltransferase (ChAT), the acetylcholine synthesizing
enzyme, was decreased, while the activity and protein
expression of acetylcholinesterase (AChE), the acetylcho-
line degrading enzyme, was found to be unaltered. In
contrast, in AD hippocampus both ChAT and AChE
enzyme activity and protein expression was decreased. Our
ﬁndings reveal an MS-speciﬁc cholinergic imbalance in the
hippocampus, which may be instrumental in terms of future
treatment options for memory problems in this disease.
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Introduction
It has been shown that 40–65% of patients suffering from
multiple sclerosis (MS) experience various degrees of
cognitive deterioration [7, 30]. Although different cogni-
tive domains may be affected, processing speed and
visuospatial memory are most frequently reported abnor-
mal [2, 4, 7, 30]. The hippocampus is critically important
for proper memory function [35], and recent studies have
shown that this brain structure is severely affected in MS
[16, 26]. In the post-mortem setting, hippocampal lesions
were found to be present in a majority of MS patients [12,
16, 26, 37] and several in vivo magnetic resonance imaging
studies also showed high numbers of hippocampal lesions
[32], as well as reduced volume [17, 33] and connectivity
[31] of the MS hippocampus.
The cholinergic neurotransmitter system plays an
essential role in learning and memory function [11, 13], and
the hippocampus is a major region of cholinergic input from
the basal forebrain [23]. Choline acetyltransferase (ChAT)
is the enzyme responsible for acetylcholine synthesis and
ChAT activity has been shown to be a reliable marker for
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brains, severe changes in the cholinergic neurotransmitter
system have long been recognized [1, 10, 15, 19, 29, 34,
41]. Degeneration of cholinergic neurons in the basal
forebrain results in a decreased cholinergic input (as indi-
cated by a decrease in ChAT activity) in the AD
hippocampus [1, 10, 15, 40]. Furthermore, acetylcholines-
terase (AChE), the acetylcholine degrading enzyme, is also
downregulated in the AD hippocampus [19, 28]. Therefore,
pharmacological treatment aiming to restore postsynaptic
availability of acetylcholine is commonly used as a ﬁrst-line
therapy for symptomatic treatment of memory impairment
in AD [3]. Whether similar changes in the cholinergic
neurotransmitter system occur in the MS hippocampus is
currently unknown.
Therefore, in this post-mortem study, we investigate
different components of the cholinergic neurotransmitter
system in the MS hippocampus, and compare these ﬁnd-
ings to hippocampus tissue of AD patients and non-
neurological controls.
Materials and methods
Hippocampal tissue
Post-mortem brain material was obtained from the Neth-
erlands Brain Bank, Amsterdam, The Netherlands. From
15 MS patients, as well as 10 donors without neurological
disease, and 10 AD patients, frozen, coronally cut hippo-
campal tissue was selected. From a subset of the cases (i.e.,
7 controls, 11 MS, and 8 AD), parafﬁn-embedded material
was also available. Non-neurological controls were care-
fully matched to the MS patient samples for post-mortem
delay, age, sex and Braak stage. Upon neuropathological
assessment, the AD cases had Braak scores [5]o f5o r
higher and were included to serve as a positive control
regarding possible cholinergic changes. Clinical and path-
ological data of the MS patients, non-neurological controls
and AD patients are provided in Table 1.
The study was approved by the institutional ethics
review board (VU University Medical Center, Amsterdam)
and all donors or their next of kin provided written
informed consent for brain autopsy and use of material and
clinical information for research purposes.
Sampling procedure
The hippocampal region, including Cornu Ammonis (CA)
1-4, identiﬁed on sections stained for proteolipid protein
(PLP) (see ‘‘Immunohistochemistry’’) were traced back in
the tissue blocks and carved with a scalpel. In order to
ensure that only the correct hippocampal areas were
isolated for an adequate comparison, cryosections were cut
before and after tissue isolation and subsequently stained
for PLP. Tissue for biochemical assays and western blot
analyses were isolated separately and were stored at -80C
until subsequent analyses.
Hippocampal lesion classiﬁcation
As described previously [16], PLP-stained hippocampal
tissue sections were scored for the presence of lesions
according to their anatomical localization. Lesions were
classiﬁed as (1) mixed intrahippocampal-perihippocampal
lesions; and (2) isolated intrahippocampal lesions (i.e.
speciﬁed for CA subﬁeld) and subsequently counted. Fur-
thermore, microglial activation, based on anti-human
leukocyte antigen-DR (HLA-DR) staining (see ‘‘Immuno-
histochemistry’’) was also examined.
Choline acetyltransferase (ChAT) activity assay
Hippocampal tissue homogenates were blinded and sam-
ples were analyzed for protein content by the Bradford
protein assay. Subsequently, a ChAT enzymatic activity
assay was performed following the technique used by
Fonnum [14] with minor modiﬁcations to the protocol [24].
Frozen hippocampal tissue which was stored at -80C was
homogenised in ice cold homogenization buffer (0.87 mM
EDTA, 0.1% Triton X-100, pH 7.0). Samples were ana-
lyzed for protein content by Bradford protein assay. An
incubation mixture (0.4 mM
14C-acetyl CoA, 1 mg/ml
BSA, 0.3 mM eserine salicylate, 0.6 M NaCl, 4 mM cho-
line chloride, 0.1 M NaH2PO4, 17.35 mM EDTA) was
prepared on ice. The experiments were set up with two
time points. Each sample was prepared in triplicate. In
addition, a total radioactivity control was set up consisting
of incubation buffer only. A blank control was set up with
only extraction buffer present. For the ﬁrst time point brain
homogenate was added to incubation buffer with a 1:1
ratio, using equal volumes (e.g. 10 ll) for each sample and
incubated at 30C. Just prior to the end incubation, brain
homogenate samples were added to incubation buffer for
without incubation. All reactions were then quenched with
the addition of ice cold dH2O. 1 ml of extraction buffer
(15% v/v acetonitrile, 85% toluene, 0.5% w/v sodium tet-
raphenylboron) was added to the experimental samples.
Eppendorfs were spun at 13,000 rpm for 2 min. 650 llo f
the upper phase was transferred into scintillant tubes.
Scintillant tubes for the controls were prepared using the
blank and total samples. 2 ml of liquid scintillant (Opti-
Phase ‘HiSafe’, Perkin Elmer, UK) was added. Tubes were
capped and radioactivity was measured in a beta counter,
for 10 min each. The activity of ChAT was measured as
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total protein (nmol/h/mg).
Acetylcholinesterase (AChE) enzyme histochemistry
On hippocampal cryosections (8 lm thick) acetylcho-
linesterase histochemist r yw a sp e r f o r m e du s i n ga
slightly modiﬁed version of the direct coloring Kar-
novsky–Roots method [21]. In short, slides were ﬁxed
for 15 min with 8% formaldehyde in 0.1 M CaCl2 and
pre-incubated for 30 min in 0.18 mM tetra-isopropyl-
pyrophosphoramide in phosphate buffered saline (iso-
ompa) to block aspeciﬁc staining. Subsequently, sections
were incubated in reaction medium (consisting of 6.5 ml
iso-ompa, 5 mg acetyl-thiocholine-iodine, 0.5 ml 1 M
sodium citrate, 1.0 ml 30 mM copper(II)sulphate, 1.0 ml
distilled water and 1.0 ml 5 mM potassium ferricyanide)
at 37C for 6 h to visualise acetylcholinesterase activity.
Table 1 Clinical data of MS patients, non-neurological controls, Alzheimer’s disease patients
Case Age
(years)
Type of
MS
Braak
stage
Sex Post-mortem delay
(h:min)
Disease duration
(years)
Cause of death
1 66 PP Braak 0 M 7:30 26 Unknown
2 49 SP Braak 0 M 8:00 25 Pneumonia
3 71 ND Braak 0 M 7:00 26 Pneumonia by aspiration
4 47 SP Braak 0 M 7:15 7 Urosepsis with organ failure
5 76 PP Braak 1 F 9:45 19 Unknown
6 63 SP Braak 0 M 7:05 24 Cardiac arrest after rupture abdominal aorta
7 77 ND Braak 1 F 5:43 Unknown Respiratory insufﬁciency with aspiration
pneumonia
8 41 SP Braak 0 F 8:25 11 Unknown
9 43 SP Braak 0 M 8:30 9 Pneumonia
10 61 SP Braak 0 M 9:15 18 Euthanasia
11 67 ND Braak 0 F 9:15 Unknown Unknown
12 71 SP Braak 0 F 10:25 24 Respiratory insufﬁciency
13 76 ND Braak 0 F 4:40 Unknown Uremia following a urinary tract infection
14 56 PP Braak 0 F 6:35 Unknown Unknown
15 44 PP Braak 0 M 12:00 13 Pneumonia
Con 56 – Braak 0 M 9:15 – Myocardial infarction
Con 80 – Braak 0 M 7:15 – Cachexia and dehydration
Con 56 – Braak 0 M 14:00 – Unknown
Con 61 – Braak 0 F 6:50 – Euthanasia
Con 84 – Braak 1 M 7:05 – Exacerbation of COPD
Con 80 – Braak 1 F 6:58 – Pulmonary embolism
Con 62 – Braak 1 F 7:55 – Euthanasia
Con 66 – Braak 1 F 7:00 – Heart failure
Con 66 – Braak 0 M 7:45 – Aneurysm
Con 84 Braak 1 M 5:35 – Heart failure
AD 68 – Braak 6 M 6:30 12 Cachexia
AD 81 – Braak 6 F 6:00 4 Pneumonia
AD 87 – Braak 5 F 9:15 8 Congestive heart failure
AD 87 – Braak 6 F 5:00 20 Cachexia
AD 64 – Braak 6 M 7:30 9 Dehydration and cachexia in end-stage AD
AD 73 – Braak 6 F 5:55 16 Unknown
AD 78 – Braak 5 F 8:25 Unknown Sepsis
AD 84 – Braak 6 M 8:05 13 Unknown
AD 82 – Braak 6 F 4:20 6 Dehydration and cachexia
AD 65 – Braak 6 M 0:59 Unknown Pneumonia
PP primary progressive MS, ND MS subtype not determined, SP secondary progressive MS, AD Alzheimer’s disease, Con non-neurological
control, M male, F female
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123For orientation cell nuclei were stained with 1%
methylgreen.
Immunohistochemistry
Five-micrometer thick frozen sections were collected on
Superfrost Plus glass slides (VWR international; Leuven,
Belgium), dried overnight at room temperature (RT) and
subsequently ﬁxed in acetone for 10 min. Then, sections
were rinsed for 3 9 10 min with 0.01 M phosphate buf-
fered saline (PBS; pH 7.4) followed by incubation with
mouse-anti-human primary antibodies against myelin pro-
teolipid protein (PLP; Clone: Plpc1; mouse IgG2a; 1:500;
Serotec, Oxford, UK) diluted in PBS containing 1% bovine
serum albumin (BSA) (Roche Diagnostics; Mannheim,
Germany) for 1 h. Subsequently, sections were rinsed with
PBS (3 9 10 min) and incubated with biotin-labeled rabbit
anti-mouse immunoglobulins F(ab0)2 (1:500) (DAKO,
Glostrup, Denmark) diluted in PBS with 1% BSA for
30 min. Then, sections were rinsed in PBS (3 9 10 min)
and incubated for 1 h at RT with streptavidin–biotin-per-
oxidase complexes (1:100; Vectastain; Vector Laboratories
Inc., Burlingame, CA, USA). Finally, sections were rinsed
with PBS (3 9 10 min) and peroxidase reaction was
developed with 3,30 diaminobenzidine-tetrahydro-
chloridedihydrate (DAB; DAKO, Glostrup, Denmark) as a
chromogen. After a short rinse with tap water, sections
were counterstained with hematoxylin for 1 min and
intensely washed with tap water for 5 min.
Eight-micrometer thick parafﬁn sections were depa-
rafﬁnized in a series of xylene (4 9 5 min), 100% ethanol,
96% ethanol, 70% ethanol. Endogenous peroxidase activity
was blocked by incubating the sections in methanol with
0.3% H2O2 for 30 min. In case of primary immunostaining
with anti-proteolipid protein (PLP) (mouse IgG2a; 1:3,000;
Serotec, Oxford, UK) sections were rinsed for 3 9 10 min
with PBS followed by incubation with primary antibodies
diluted in PBS containing 1% BSA for 1 h. In case of
primary immunostaining with anti-HLA-DR, sections were
pretreated with microwave antigen retrieval (3 min at
900 W and 30 min at 180 W). After pretreatment, sections
were cooled to room temperature, rinsed with PBS
(3 9 10 min) and incubated with anti-HLA-DR (mouse
IgG2b; 1:50, generous gift from Dr. Hilgers, VUMC,
Amsterdam) diluted in PBS containing 1% BSA for 1 h.
Then, sections were rinsed again with PBS (3 9 10 min)
and incubated with EnVision horseradish peroxidase
(HRP) complex (DAKO, Glostrup, Denmark) and ﬁnally
with 3,30 diaminobenzidine-tetrahydrochloridedihydrate
(DAB; DAKO, Glostrup, Denmark) as a chromogen. After
a short rinse with tap water, sections were counterstained
with hematoxylin for 1 min and intensely washed with tap
water for 5 min.
For immunostaining with anti-ChAT (AB144P, goat
polyclonal, 1:400, Millipore, Billerica, MA, USA) sections
were deparafﬁnized and rehydrated as described above.
Subsequently, sections were incubated with 37% formal-
dehyde for 10 min and then rinsed with distilled water
(2 9 5 min). Then, sections were rinsed with citrate buffer
(pH 6.0) (3 9 10 min) and ﬁnally rinsed overnight in cit-
rate buffer at 4C. The other day the slides were again
rinsed for 2 9 10 min with citrate buffer and then 10 min
in tris-buffered saline (TBS; pH 7.6). Hereafter, endoge-
nous peroxidase activity was blocked by incubating the
sections with TBS with 3% H2O2 for 30 min. Then, sec-
tions were rinsed with TBS (10 min) and citrate buffer
(2 9 10 min). Subsequently, sections were pretreated by
microwave antigen retrieval (3 min at 900 W and 30 min
at 180 W) in citrate buffer. After pretreatment, sections
were cooled to room temperature and rinsed with TBS
(3 9 10 min). Then, sections were incubated with 5%
normal rabbit serum (DAKO, Glostrup, Denmark) in TBS
with 0.5% Triton X-100 (TBS-Tx) for 30 min and then
with primary antibodies diluted in TBS-Tx containing 2%
normal rabbit serum for 2 h at RT and subsequently 48 h at
4C. After 2 days, sections were rinsed again with TBS
(3 9 10 min) followed by 1 h incubation with biotin-
labeled rabbit-anti-goat antibodies (DAKO, Glostrup,
Denmark) diluted in TBS-Tx. Subsequently, sections were
rinsed in TBS (3 9 10 min) and incubated for 1 h at RT
with streptavidin–biotin-peroxidase complexes (1:100;
Vectastain; Vector Laboratories Inc., Burlingame, CA,
USA) diluted in TBS-Tx. After two rinse steps (10 min) in
TBS, sections were rinsed with Tris-hydrochloride (pH 7.6)
for 10 min and then incubated with 3,30 diaminobenzidine-
tetrahydrochloridedihydrate (DAB; DAKO, Glostrup,
Denmark) as a chromogen. After a short rinse in TBS-
hydrochloride (39), sections were counterstained with
hematoxylin for 1 min and intensely washed with tap water
for 5 min. For all immunostainings performed, negative
controls were prepared by incubation without primary or
secondary antibody and gave no immunoreactivity.
Western blot analysis
For protein analysis, 30 hippocampal sections of 10-lm
thick were isolated from 7 controls, 9 MS and 7 AD
patients as described in ‘‘Sampling procedure’’. Subse-
quently, tissue was homogenized by incubating the samples
with radio-immunoprecipation assay (RIPA) buffer and
protease inhibitors (Sigma-Aldrich, Zwijndrecht, The
Netherlands) on ice for 30 min followed by soniﬁcation
(Branson soniﬁer, Danbury, CT, USA). The protein con-
centration was measured with the bicinchoninic acid
(BCA) protein assay (Pierce, Perbio Science, Etten-Leur,
The Netherlands) as indicated in the user manual, using
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stored at -80C until assayed.
Equal amounts of protein (10 lg) were separated on
10% SDS-PAGE gels (Bio-Rad Laboratories, CA, USA)
and transferred to PVDF membranes (Bio-Rad). After
blocking in PBS and Odyssey blocking buffer (1:1) (LI-
COR Biosciences, Lincoln NE, USA), membranes were
incubated with primary antibody anti-AChE (PAB6747,
goat polyclonal, 1:2,000, Abnova, Walnut, CA, USA)
overnight at 4C. Then, membranes were rinsed in PBS
containing 0.1% Tween-20 (4 9 5 min) and incubated
with donkey-anti-goat-IRDye
 800CW infrared dye
(1:15,000) (LI-COR Biosciences) diluted in PBS, Odyssey
blocking buffer (1:1), 0.1% Tween-20 and 0.01% SDS for
1 h at RT. Finally, the membranes were rinsed in PBS and
0.1% Tween-20 (4 9 5 min), 3 times in PBS and then
membranes were analyzed using a Odyssey Infrared
Imaging system (LI-COR Biosciences) and relevant signal
intensity was quantiﬁed with LI-COR analysis software.
Molecular weight and predicted band size of AChE is
68 kDa. After this, the membranes were incubated (over-
night at 4C) with the primary antibody anti-lactate
dehydrogenase (1:20,000) (LDH; ab52448, rabbit mono-
clonal, Abcam, Cambridge, UK). Molecular weight and
predicted band size of LDH is 37 kDa. After this, mem-
branes were incubated with goat-anti-rabbit-IRDye

800CW infrared dye (1:15,000) (LI-COR Biosciences)
diluted in PBS, Odyssey blocking buffer (1:1), 0.1%
Tween-20 and 0.01% SDS for 1 h at RT and analyzed as
describe above and subsequently relative AChE protein
expression was quantiﬁed.
Quantiﬁcation of (immuno)histochemical stainings
(Immuno)histochemically stained sections were scanned
with a Mirax slide scanner system (3DHISTECH, Buda-
pest, Hungary). Digital images scanned with a 209
objective were captured in three randomly selected areas of
each of the hippocampal subﬁelds (CA1, CA3-2 and CA4)
for ChAT immunostainings and AChE histochemical sta-
inings. As already indicated above, parafﬁn-embedded
material was available from 7 control, 8 AD and 11 MS
hippocampi and this material was therefore immunohisto-
chemically stained for ChAT. For each investigated
hippocampal subﬁeld (i.e. CA1, CA2-3 and CA4), three
randomly selected areas were captured for subsequent
quantiﬁcation. This means that for controls a total of 21
(3 9 7), for AD 24 (3 9 8) and for MS 33 (3 9 11) ran-
domly chosen areas were captured. For the control, AD and
MS hippocampal sections (frozen) on which AChE enzyme
histochemistry was performed, respectively 30 (3 9 10),
30 (3 9 10) and 45 (3 9 15) randomly selected areas from
each hippocampal subﬁeld were captured for subsequent
quantiﬁcation. The (immuno)reactivity of the stainings was
scored in a blinded fashion with respect to the presence of
demyelinated lesions in order to avoid potential bias (e.g.
by the expectation that lesional areas should show more
pronounced cholinergic system changes). However, dif-
ferences in terms of cholinergic alterations between
lesional and perilesional or non-lesional areas was retro-
spectively assessed. The relative amount of staining was
analyzed using a, for this staining, tailor-made batch mode
ImageJ macro as previously described [18]. ImageJ is
freely available at: http://rsb.info.nih.gov/ij/index.html (US
National Institutes of Health, Bethesda, MD, USA).
Statistics
GraphPad Prism software (San Diego, CA, USA) was
used for the statistical analyses. In case of normal dis-
tribution of data, analysis of variance (ANOVA) with
Dunnet’s correction for multiple comparisons was used to
compare differences among the control, MS and AD
groups, with the control group as a reference point. When
normality was not found, the non-parametric Kruskal–
Wallis test was used with a Dunn’s correction for mul-
tiple comparisons. Results were considered signiﬁcant
when p\0.05.
Results
Hippocampal demyelination
None of the control or AD hippocampus samples showed
any sign of demyelination (Fig. 1a, b). As for MS, 12 out
of 15 MS hippocampus samples were partly or completely
demyelinated (Fig. 1c). More speciﬁcally, a total number
of 25 lesions were found of which 14 lesions were mixed
intrahippocampal-perihippocampal lesions and 11 lesions
were isolated intrahippocampal lesions. Only three MS
hippocampi showed no demyelination (Fig. 1d). This is in
line with our previous observations [16] and with post-
mortem ﬁndings of other groups [12, 26]. In addition, as
described in detail before [16], our MS samples indicated
slightly enhanced microglia activation, as reﬂected by
increased HLA-DR immunopositivity, in hippocampal
areas where the myelin was still intact (data not shown).
Furthermore, as expected based on the literature [16, 26,
37], no lymphocyte/macrophage inﬁltration was found in
the MS hippocampal lesions.
Hippocampal ChAT activity and protein expression
The biochemical assay revealed differences in mean hip-
pocampal ChAT activity levels among the control, MS and
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reduction in ChAT activity level of 43% was found in MS
hippocampi compared to controls (Fig. 2a; MS vs. Con,
mean of 1.00 vs. 1.74 nmol acetylcholine/h/mg protein;
p\0.05). A mean reduction of 45% was found in AD
hippocampi compared to controls (Fig. 2a; AD vs. Con,
mean of 0.96 vs. 1.74 nmol acetylcholine/h/mg protein; not
signiﬁcant after Dunn’s correction).
Compared to control hippocampus (Fig. 2b–d), immu-
nohistochemical staining for ChAT was reduced in the
different hippocampal subﬁelds (CA4, CA3-2 and CA1) in
MS (Fig. 2e–g) and AD (Fig. 2h–j). Subsequently, detailed
quantiﬁcation of digitized images revealed a signiﬁcant and
substantial decrease in ChAT immunoreactivity in CA4 in
MS (mean 80% reduction) and AD hippocampi (mean 92%
reduction) (Fig. 2k, Kruskal–Wallis; p = 0.0023; after
correction: Con vs. MS: p\0.05 and Con vs. AD:
p\0.01). Although less prominently, ChAT immunore-
activity was also decreased in CA3-2 in MS (mean 57%
reduction) and AD hippocampus (mean 81% reduction)
(Fig. 2l, Kruskal–Wallis; p = 0.0035; after correction: Con
vs. MS: not signiﬁcant and Con vs. AD: p\0.01). Finally,
ChAT immunoreactivity was decreased in CA1 in MS
(mean 59% reduction) and in AD (mean 85% reduction)
(Fig. 2m, Kruskal–Wallis; p = 0.0019; after correction:
Con vs. MS: p\0.05 and Con vs. AD: p\0.01). Retro-
spective examination of the MS samples showed that the
decrease in ChAT immunoreactivity was present irrespec-
tive of demyelination (data not shown).
Fig. 1 Hippocampus anatomy and hippocampal demyelination of the
MS samples. Hippocampus tissue from controls, AD and MS patients
were immunohistochemically stained for anti-proteolipid protein and
revealed a as expected, no sign of demyelination in any of the control
hippocampus samples. Cornu Ammonis subﬁelds of the hippocampus
(CA4, CA3-2, CA1), as well as the ﬁmbria, are indicated. b None of
the AD hippocampus samples showed any demyelination, (c) while
12 out of 15 MS patients showed demyelinated lesions. Black arrows
indicate demyelination in CA4, CA3-2 and CA1. The white arrow
indicates a small preserved area of normal myelination in CA1. d 3
out of 15 MS hippocampi were not affected by demyelination
Fig. 2 Reduced ChAT activity and ChAT protein expression in MS
hippocampus. a Statistically signiﬁcant differences among the three
different groups were found regarding the hippocampal choline
acetyltransferase (ChAT) activity (Kruskal–Wallis: p = 0.026). In
MS hippocampus compared to control hippocampus, a mean reduc-
tion in ChAT activity of 43% was found (after Dunn’s correction:
p\0.05). In AD hippocampus compared to control hippocampus, a
mean reduction of 45% was found in ChAT activity (after Dunn’s
correction: not signiﬁcant). Non-neurological control hippocampus
immunohistochemically stained with anti-ChAT, revealed ChAT
immunopositive neurites (arrows in the insets) in CA4 (b), CA3-2
(c) and CA1 (d). In all MS hippocampal subﬁelds (e CA4, f CA3-2,
g CA1), ChAT immunopositivity was clearly decreased as compared
to control tissue, although bead-like varicosities were occasionally
observed (arrows in the insets). In AD hippocampus, a decrease of
ChAT immunopositivity was also found in CA4 (h), CA3-2 (i) and
CA1 (j), with occasional immunopositive bead-like varicosities
(arrows in the insets). Quantiﬁcation of ChAT immunostainings
revealed reductions of the amount of staining in MS and AD
hippocampus in (k) CA4 (Con vs. MS: p\0.05; Con vs. AD:
p\0.01), (l) CA3-2 (Con vs. MS: not signiﬁcant; Con vs. AD:
p\0.01) and (m) CA4 (Con vs. MS: p\0.05; Con vs. AD:
p\0.01). Original magniﬁcations: (b-j) 9200 and 9630 (insets).
Error bars indicate SEM. *p\0.05, **p\0.01, ns not signiﬁcant
c
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EnzymehistochemistryforAChErevealednodifferencesin
the reaction product formed in the different hippocampal
subﬁelds when comparing control (Fig. 3a) and MS
(Fig. 3b) hippocampus, indicating an unaltered AChE
activity in MS hippocampus. In line with previous results
[19],thereactionproductwasdecreasedinADhippocampus
(Fig. 3c). Digital analyses conﬁrmed no differences in the
reaction product in MS and control hippocampus in all
hippocampal subﬁelds (Fig. 3d–f). Retrospectively, exami-
nationoftheMSsamplesindicatedthatlesionalareasdidnot
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activity (data not shown). In hippocampus tissue of AD
patients, decreased AChE activity was found in CA4 and
CA1 (Fig. 3d, f; p\0.01 and p\0.05, respectively).
Subsequent western blot analysis conﬁrmed decreased pro-
teinexpressionlevelsofAChEinADhippocampus(Fig. 3g,
h; p\0.05), but no differences in AChE protein expression
in MS and control hippocampus (Fig. 3g, h).
Discussion
In the current study, a clear reduction of ChAT activity and
ChAT protein expression was found in the MS
hippocampus, with unchanged AChE protein expression
levels and enzyme activity, which is in line with a recent
positron emission tomography study [38]. Our ﬁndings
suggest that a selective imbalance exists in the hippo-
campal cholinergic neurotransmission of MS patients, with
reduced synthesis of acetylcholine but an unaltered deg-
radation of the neurotransmitter. This imbalance was not
found in AD.
Cholinergic neurons in se are not localized within the
human hippocampus, and this brain structure receives its
main cholinergic input from the basal forebrain [23]. The
basal forebrain consists of several nuclei: the cholinergic
neurons in the nucleus basalis of Meynert and the hori-
zontal limb of the diagonal band nucleus mainly innervate
Fig. 3 Unchanged AChE activity and protein expression in MS
hippocampus. The activity of AChE as reﬂected by the amount of
reaction product formed was equal in a non-neurological control
hippocampus and b MS hippocampus in all hippocampal subﬁelds. In
contrast, in c AD hippocampus, the formed reaction product was
clearly decreased in CA4 (asterisk) and CA1 (hash), but not in CA3-2
(dagger), indicating a decreased activity of AChE in these areas.
Quantiﬁcation of the reaction product formed by AChE in the
(d) CA4 hippocampal subﬁeld indicated differences among the three
groups (ANOVA: p = 0.003, Dunnet correction revealed Con vs. AD
and MS vs. AD: p\0.01; Con vs. MS: no signiﬁcant difference). For
the CA3-2 subﬁeld (e), no differences were found between the three
groups (Kruskal–Wallis: p = 0.175). For the CA1 subﬁeld (f) differ-
ences among the three groups were found (ANOVA: p = 0.013,
Dunnet correction revealed Con vs. AD and MS vs. AD: p\0.05;
Con vs. MS: no signiﬁcant difference). g Representative western blot
of 3 control, 3 MS and 3 AD samples indicated decreased protein
expression of AChE in AD hippocampus, but not in MS hippocampus
tissue. h Quantiﬁcation of protein expression levels of AChE of all
samples included indicated signiﬁcant differences among the three
different groups (ANOVA: p = 0.015, Dunnet correction revealed
Con vs. AD and MS vs. AD: p\0.05; Con vs. MS: no signiﬁcant
difference). Error bars indicate SEM. *p\0.05, **p\0.01, ns not
signiﬁcant
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123the olfactory bulb, the amygdala and the cerebral cortex
[23], whereas the cholinergic neurons associated with the
vertical nucleus of the diagonal band and the medial septal
nucleus mainly innervate the hippocampal complex [23].
The cholinergic pathways extending from the vertical
nucleus and the medial septal nucleus predominantly travel
within the fornix. Of interest, in a post-mortem study by
Huitinga et al. [20] it was reported that the hypothalamus
and adjacent ﬁber bundles, including the fornix, were
affected by (active) demyelination in 16 out of the 17 MS
patients studied. It is, therefore, tempting to speculate that
demyelinating processes in these areas, co-occurring with
axonal damage and loss [36], lead to a cholinergic deﬁcit
within the MS hippocampus. However, we were unfortu-
nately not able to investigate lesions in the fornix of the MS
patients included in this study, therefore future studies are
warranted to investigate this possible correlation. Interest-
ingly, hippocampal cholinergic deﬁcits were found both in
demyelinated and non-demyelinated MS hippocampi,
although our sample size of non-demyelinated MS hippo-
campi was low (n = 3) to deﬁnitively conclude that
cholinergic changes are completely lesion-independent.
The fact that demyelination and degenerative changes in
the neuropil are not necessarily coupled processes in MS
was also shown by a post-mortem study by Wegner et al.
[39] who found an overall lesion-independent neocortical
thinning of *10% in MS brains indicating that other
mechanisms than cortical demyelination may contribute to
grey matter pathology in MS.
As reported extensively in AD literature [1, 10, 15, 19,
29, 34, 41], and replicated in this study (although not sta-
tistically signiﬁcant for ChAT activity, probably due to a
small AD sample size), our study now also implicates a
decreased cholinergic input in the hippocampus of MS
patients. As the cholinergic neurotransmitter system has an
important role in learning and memory function [11, 13],
decreased cholinergic function within the MS hippocampus
may be expected to contribute to these memory complaints
as experienced by a signiﬁcant proportion of the MS
patients [2, 4, 7, 30]. Indeed, although medical information
was sparse for our post-mortem study, cognitive deﬁcits
had been speciﬁcally reported in the majority of the MS
cases included in this study. Future studies investigating
hippocampus-dependent cognitive disturbances in MS
patients should now be set up in order to study direct causal
relationships with the cholinergic abnormalities found in
the current study. Interestingly, a magnetic resonance
imaging study indicated that cholinergic pathways are
more heavily affected in MS patients who scored worse on
visuospatial memory tests [6].
Pharmacological manipulation of the cholinergic system,
by elevating the postsynaptic acetylcholine content using
acetylcholinesterase inhibitors, has repeatedly been proven
tobesuccessfulinAD[3]in(temporarily)restoringlearning
and memory function. First tentative explorations in an
animalmodelofMS[9,25]andinasmallclinicaltrialonMS
patients [22] showed beneﬁcial effects in cognitive perfor-
mance following the use of acetylcholinesterase inhibitors.
Additionally, the use of the acetylcholinesterase inhibitor
rivastigminewasfoundtoenhancefunctionalbrainadaptive
changes related to cognitive processing in MS patients [27].
Our neuropathological and neurochemical ﬁndings indeed
verify that extensive, and possibly treatable, abnormalities
are present in the MS hippocampus. However, our data also
show that, compared to AD, MS cases have an imbalance of
acetylcholine producing and degrading enzymes.
In MS, hippocampal lesions lack lymphocyte/macro-
phage inﬁltration [16, 26, 37]. Hence, it is unlikely that our
western blot and enzyme activity results have been inﬂu-
enced by major differences in cellularity. What causes this
difference in the cholinergic system between the two
neurodegenerative diseases, and how it may possibly affect
treatment schemes, is at present unclear and should be the
focus of future investigation. Furthermore, as a recent
microarray-based study [12] found changes in the gluta-
mate neurotransmitter system in the MS hippocampus, it
will also be interesting to see how abnormalities in dif-
ferent neurotransmitter systems may cooperate in the
development of cognitive decline in MS.
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